• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨肉瘤与转移

Osteosarcoma and Metastasis.

作者信息

Sheng Gaohong, Gao Yuan, Yang Yong, Wu Hua

机构信息

Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出版信息

Front Oncol. 2021 Dec 10;11:780264. doi: 10.3389/fonc.2021.780264. eCollection 2021.

DOI:10.3389/fonc.2021.780264
PMID:34956899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8702962/
Abstract

Osteosarcoma is the most common primary bone malignancy in adolescents. Its high propensity to metastasize is the leading cause for treatment failure and poor prognosis. Although the research of osteosarcoma has greatly expanded in the past decades, the knowledge and new therapy strategies targeting metastatic progression remain sparse. The prognosis of patients with metastasis is still unsatisfactory. There is resonating urgency for a thorough and deeper understanding of molecular mechanisms underlying osteosarcoma to develop innovative therapies targeting metastasis. Toward the goal of elaborating the characteristics and biological behavior of metastatic osteosarcoma, it is essential to combine the diverse investigations that are performed at molecular, cellular, and animal levels from basic research to clinical translation spanning chemical, physical sciences, and biology. This review focuses on the metastatic process, regulatory networks involving key molecules and signaling pathways, the role of microenvironment, osteoclast, angiogenesis, metabolism, immunity, and noncoding RNAs in osteosarcoma metastasis. The aim of this review is to provide an overview of current research advances, with the hope to discovery druggable targets and promising therapy strategies for osteosarcoma metastasis and thus to overcome this clinical impasse.

摘要

骨肉瘤是青少年中最常见的原发性骨恶性肿瘤。其高转移倾向是治疗失败和预后不良的主要原因。尽管在过去几十年中骨肉瘤的研究有了很大进展,但针对转移进展的知识和新治疗策略仍然匮乏。发生转移的患者预后仍然不尽人意。迫切需要深入透彻地了解骨肉瘤的分子机制,以开发针对转移的创新疗法。为了阐述转移性骨肉瘤的特征和生物学行为,有必要将从基础研究到临床转化、跨越化学、物理科学和生物学等多个领域、在分子、细胞和动物水平上进行的各种研究结合起来。本综述重点关注骨肉瘤转移过程、涉及关键分子和信号通路的调控网络、微环境、破骨细胞、血管生成、代谢、免疫以及非编码RNA在骨肉瘤转移中的作用。本综述旨在概述当前的研究进展,希望能发现可成药靶点以及有前景的骨肉瘤转移治疗策略,从而克服这一临床难题。

相似文献

1
Osteosarcoma and Metastasis.骨肉瘤与转移
Front Oncol. 2021 Dec 10;11:780264. doi: 10.3389/fonc.2021.780264. eCollection 2021.
2
Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.理解和模拟转移生物学以改进对抗骨肉瘤进展的治疗策略。
Front Oncol. 2020 Jan 31;10:13. doi: 10.3389/fonc.2020.00013. eCollection 2020.
3
The interaction between osteosarcoma and other cells in the bone microenvironment: From mechanism to clinical applications.骨肉瘤与骨微环境中其他细胞之间的相互作用:从机制到临床应用
Front Cell Dev Biol. 2023 May 3;11:1123065. doi: 10.3389/fcell.2023.1123065. eCollection 2023.
4
MicroRNAs in osteosarcoma: from biological players to clinical contributors, a review.骨肉瘤中的微小RNA:从生物学参与者到临床贡献者,综述
J Int Med Res. 2013 Feb;41(1):1-12. doi: 10.1177/0300060513475959. Epub 2013 Jan 24.
5
New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?原发性骨肿瘤及其微环境中 Wnt/β-连环蛋白信号通路的新见解:开发治疗策略的有前途靶点?
Int J Mol Sci. 2019 Jul 31;20(15):3751. doi: 10.3390/ijms20153751.
6
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.骨肉瘤的免疫治疗:基础机制、原理和最新突破。
Cancer Lett. 2021 Mar 1;500:1-10. doi: 10.1016/j.canlet.2020.12.024. Epub 2020 Dec 23.
7
Bone Microenvironment and Osteosarcoma Metastasis.骨微环境与骨肉瘤转移。
Int J Mol Sci. 2020 Sep 23;21(19):6985. doi: 10.3390/ijms21196985.
8
Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis.解析肿瘤微环境在骨肉瘤进展和转移中的影响
Cancers (Basel). 2023 Oct 23;15(20):5108. doi: 10.3390/cancers15205108.
9
Noncoding RNAs in osteosarcoma: Implications for drug resistance.非编码 RNA 在骨肉瘤中的作用:与耐药性的关系。
Cancer Lett. 2021 Apr 28;504:91-103. doi: 10.1016/j.canlet.2021.02.007. Epub 2021 Feb 12.
10
Role of ezrin in osteosarcoma metastasis.埃兹蛋白在骨肉瘤转移中的作用。
Adv Exp Med Biol. 2014;804:181-201. doi: 10.1007/978-3-319-04843-7_10.

引用本文的文献

1
Molecular and Glycosylation Pathways in Osteosarcoma: Tumor Microenvironment and Emerging Strategies Toward Personalized Oncology.骨肉瘤中的分子和糖基化途径:肿瘤微环境与个性化肿瘤学的新兴策略
Curr Issues Mol Biol. 2025 Aug 7;47(8):629. doi: 10.3390/cimb47080629.
2
Molecular Crosstalk Between RUNX2 and HIF-1α in Osteosarcoma: Implications for Angiogenesis, Metastasis, and Therapy Resistance.骨肉瘤中RUNX2与HIF-1α之间的分子串扰:对血管生成、转移和治疗抗性的影响
Int J Mol Sci. 2025 Aug 7;26(15):7642. doi: 10.3390/ijms26157642.
3
Cluster of differentiation 133 (CD133) and C-X-C chemokine receptor 4 (CXCR4) associated with the incidence of metastasis in osteosarcoma patients.

本文引用的文献

1
miRNA-221-3p derived from M2-polarized tumor-associated macrophage exosomes aggravates the growth and metastasis of osteosarcoma through SOCS3/JAK2/STAT3 axis.M2 极化肿瘤相关巨噬细胞来源的 exosomes 中的 miRNA-221-3p 通过 SOCS3/JAK2/STAT3 轴加重骨肉瘤的生长和转移。
Aging (Albany NY). 2021 Aug 13;13(15):19760-19775. doi: 10.18632/aging.203388.
2
Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.当前骨肉瘤靶向抗血管生成治疗的研究进展。
Cell Prolif. 2021 Sep;54(9):e13102. doi: 10.1111/cpr.13102. Epub 2021 Jul 26.
3
Osteosarcoma and Metastasis Associated Bone Degradation-A Tale of Osteoclast and Malignant Cell Cooperativity.
分化簇133(CD133)和C-X-C趋化因子受体4(CXCR4)与骨肉瘤患者的转移发生率相关。
Eur J Orthop Surg Traumatol. 2025 Jul 23;35(1):318. doi: 10.1007/s00590-025-04434-x.
4
Development and validation of a predictive score for chemoresistance in high-grade osteosarcoma at baseline.高级别骨肉瘤基线化疗耐药预测评分的开发与验证
Front Med (Lausanne). 2025 Jul 4;12:1588302. doi: 10.3389/fmed.2025.1588302. eCollection 2025.
5
Systemic strategies for osteosarcoma: advances and future directions.骨肉瘤的全身治疗策略:进展与未来方向
Discov Oncol. 2025 Jul 18;16(1):1367. doi: 10.1007/s12672-025-02208-9.
6
Urolithin A suppressed osteosarcoma cell migration and invasion via targeting MMPs and AKT1.尿石素A通过靶向基质金属蛋白酶(MMPs)和蛋白激酶B1(AKT1)抑制骨肉瘤细胞的迁移和侵袭。
Sci Rep. 2025 Jul 17;15(1):25941. doi: 10.1038/s41598-025-11804-2.
7
Whole‑exome evolutionary profiling of osteosarcoma uncovers metastasis‑related driver mutations and generates an independently validated predictive classifier.骨肉瘤的全外显子组进化分析揭示了与转移相关的驱动突变,并生成了一个经独立验证的预测分类器。
J Transl Med. 2025 Jul 7;23(1):746. doi: 10.1186/s12967-025-06796-6.
8
Comparison of Differentially Expressed Genes in Human and Canine Osteosarcoma.人类与犬骨肉瘤中差异表达基因的比较
Life (Basel). 2025 Jun 12;15(6):951. doi: 10.3390/life15060951.
9
Osteosarcoma: current insights and advances.骨肉瘤:当前的见解与进展
Explor Target Antitumor Ther. 2025 Jun 15;6:1002324. doi: 10.37349/etat.2025.1002324. eCollection 2025.
10
Silencing of AEBP1 inhibits proliferation and promotes apoptosis via the AKT signaling pathway in osteosarcoma.AEBP1基因沉默通过AKT信号通路抑制骨肉瘤细胞增殖并促进其凋亡。
Biomed Rep. 2025 May 30;23(2):128. doi: 10.3892/br.2025.2006. eCollection 2025 Aug.
骨肉瘤与转移相关的骨降解——破骨细胞与恶性细胞协同作用的故事。
Int J Mol Sci. 2021 Jun 25;22(13):6865. doi: 10.3390/ijms22136865.
4
The Effect of Fluid Flow Shear Stress and Substrate Stiffness on Yes-Associated Protein (YAP) Activity and Osteogenesis in Murine Osteosarcoma Cells.流体流动剪切应力和底物硬度对小鼠骨肉瘤细胞中Yes相关蛋白(YAP)活性和成骨作用的影响
Cancers (Basel). 2021 Jun 23;13(13):3128. doi: 10.3390/cancers13133128.
5
Osteosarcoma-Derived Small Extracellular Vesicles Enhance Tumor Metastasis and Suppress Osteoclastogenesis by miR-146a-5p.骨肉瘤来源的小细胞外囊泡通过miR-146a-5p增强肿瘤转移并抑制破骨细胞生成。
Front Oncol. 2021 May 4;11:667109. doi: 10.3389/fonc.2021.667109. eCollection 2021.
6
Macrophages-derived exosomal lncRNA LIFR-AS1 promotes osteosarcoma cell progression via miR-29a/NFIA axis.巨噬细胞来源的外泌体长链非编码RNA LIFR-AS1通过miR-29a/NFIA轴促进骨肉瘤细胞进展。
Cancer Cell Int. 2021 Apr 1;21(1):192. doi: 10.1186/s12935-021-01893-0.
7
Plasma Exosome-Derived Sentrin SUMO-Specific Protease 1: A Prognostic Biomarker in Patients With Osteosarcoma.血浆外泌体来源的Sentrin SUMO特异性蛋白酶1:骨肉瘤患者的一种预后生物标志物。
Front Oncol. 2021 Mar 9;11:625109. doi: 10.3389/fonc.2021.625109. eCollection 2021.
8
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.骨肉瘤的免疫治疗:基础机制、原理和最新突破。
Cancer Lett. 2021 Mar 1;500:1-10. doi: 10.1016/j.canlet.2020.12.024. Epub 2020 Dec 23.
9
LncRNA CASC15 is Upregulated in Osteosarcoma Plasma Exosomes and CASC15 Knockdown Inhibits Osteosarcoma Progression by Regulating miR-338-3p/RAB14 Axis.长链非编码RNA CASC15在骨肉瘤血浆外泌体中上调,敲低CASC15通过调节miR-338-3p/RAB14轴抑制骨肉瘤进展。
Onco Targets Ther. 2020 Nov 23;13:12055-12066. doi: 10.2147/OTT.S282053. eCollection 2020.
10
Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis.肿瘤细胞 MT1-MMP 对于骨肉瘤肿瘤生长、骨质降解和肺转移是可有可无的。
Sci Rep. 2020 Nov 5;10(1):19138. doi: 10.1038/s41598-020-75995-6.